1. Apoptosis
  2. RIP kinase
  3. GSK547

GSK547 

目录号: HY-114492
产品使用指南

GSK547 是一种高效的选择性 receptor-interacting serine/threonine protein kinase 1 (RIP1) 抑制剂,可抑制巨噬细胞介导的胰腺癌适应性免疫耐受。

MCE 的所有产品仅用作科学研究,我们不为任何个人用途提供产品和服务

GSK547 Chemical Structure

GSK547 Chemical Structure

CAS No. : 2226735-55-1

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

Size Stock
250 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Customer Review

Other Forms of GSK547:

Top Publications Citing Use of Products
  • 生物活性

  • 技术信息

  • 纯度 & 产品资料

  • 参考文献

Description

GSK547, a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIP1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer[1].

IC50 & Target

RIP1[1]

In Vitro

GSK547 (0.1-100000 nM; 24 hours) pretreats L929 cells with recombinant TNFα and zVAD at various doses for 30 min, then cell death is induced with an IC50 of 32 nM after 24 hours[1].
GSK547 up-regulates STAT1 signaling in bone marrow-derived macrophages (BMDM)[1].

Cell Viability Assay[1]

Cell Line: L929 cells (Mouse L-cells NCTC 929)
Concentration: 0.1 nM; 10 nM; 1000 nM; 100000 nM
Incubation Time: 24 hours
Result: Reduced viability of L929 cells after co-treatment with TNFα and zVAD with an IC50 of 32 nM.

Western Blot Analysis[1]

Cell Line: Bone marrow-derived macrophages (BMDM)
Concentration:
Incubation Time: 30 minutes
Result: Up-regulated STAT1 signaling in BMDM.
In Vivo

GSK547 (GSK′547; RIP1i) robustly targets RIP1 in vivo. RIP1 inhibition results in immunogenic macrophage differentiation in pancreatic cancer, leading to adaptive immune activation and tumor protection for pancreatic ductal adenocarcinoma (PDA)[1].
GSK547 (100 mg/kg/day; fed via food-based dosing; 15-50 days) reduces tumor burden and extends survival compared with mice treated with controls or Nec-1s[1].

Animal Model: The wild-type (WT) mice orthotopically implanted with Pdx1Cre;KrasG12D;Trp53R172H (KPC)-derived tumor cells[1]
Dosage: ~100 mg/kg
Administration: Fed via food-based dosing, daily, 15-50 days
Result: Reduced tumor burden and extended survival.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility
In Vitro: 

DMSO : ≥ 125 mg/mL (315.35 mM)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5228 mL 12.6138 mL 25.2277 mL
5 mM 0.5046 mL 2.5228 mL 5.0455 mL
10 mM 0.2523 mL 1.2614 mL 2.5228 mL
* 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存方式和期限。
In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案,配制前请先配制澄清的储备液,再依次添加助溶剂 (为保证实验结果的可靠性,体内实验的工作
液,建议您现用现配,当天使用;澄清的储备液可以根据储存条件,适当保存;以下溶剂前的百分比是指该溶剂在您配制终溶液中的体积占比):

  • 1.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (5.25 mM); Clear solution

  • 2.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (5.25 mM); Clear solution

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (5.25 mM); Clear solution

*以上所有助溶剂都可在 MCE 网站选购。
References
Molecular Weight

396.39

Formula

C₂₀H₁₈F₂N₆O

CAS No.

2226735-55-1

SMILES

N#CC1=NC=NC(N2CCC(C(N3N=CC[C@H]3C4=CC(F)=CC(F)=C4)=O)CC2)=C1

Shipping

Room temperature in continental US; may vary elsewhere

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
GSK547
目录号:
HY-114492
需求量:

GSK547

Cat. No.: HY-114492